IGFBP-3: Which Tests to Order Alongside It

What Is IGFBP-3 and Why Does It Matter?

IGFBP-3 is the most abundant of the six insulin-like growth factor binding proteins, and it carries roughly 75 to 80% of circulating IGF-1 as part of a ternary complex with the acid-labile subunit (ALS) (Baxter RC, 2014, Nat Rev Cancer). Without measuring IGFBP-3, you are seeing only part of the GH-axis picture.

The Ternary Complex

The ternary complex consists of IGF-1, IGFBP-3, and ALS. When this complex circulates intact, IGF-1 has a half-life of roughly 12 to 15 hours. Free IGF-1 alone has a half-life under 10 minutes. That biochemical fact is why IGFBP-3 concentrations track GH secretion over days rather than minutes, making it a more stable biomarker than a random GH draw (Rajaram S et al., 1997, Endocr Rev).

GH Dependence

Growth hormone directly stimulates hepatic IGFBP-3 synthesis. States of GH excess (acromegaly, exogenous GH misuse) push IGFBP-3 up. States of GH deficiency, liver dysfunction, or severe malnutrition push it down. The Endocrine Society's 2011 Clinical Practice Guideline on GH Deficiency in Adults states: "Serum IGF-1 is the single best screening test for GHD, and IGFBP-3 may provide additional information particularly in young children and in patients with borderline IGF-1 results." (Molitch ME et al., 2011, J Clin Endocrinol Metab)

Clinical Bottom Line

A stand-alone IGFBP-3 result is rarely actionable. The number gains clinical meaning only when placed alongside IGF-1, a clinical history, and (when indicated) dynamic GH testing.

Normal IGFBP-3 Ranges by Age and Sex

Reference intervals for IGFBP-3 are strongly age-dependent, which means applying an adult reference range to a 10-year-old produces misleading results. Labs such as Mayo Clinic Laboratories and ARUP report age- and sex-stratified ranges because IGFBP-3 peaks in adolescence and declines progressively after age 30 (Juul A, 2003, Best Pract Res Clin Endocrinol Metab).

Approximate Adult Reference Ranges

| Age Group | Approximate IGFBP-3 Range (mg/L) | |-----------|----------------------------------| | 20 to 30 years | 3.4 to 7.8 | | 31 to 40 years | 3.0 to 7.0 | | 41 to 50 years | 2.6 to 6.5 | | 51 to 60 years | 2.2 to 5.7 | | Over 60 years | 1.8 to 5.2 |

These are approximate values derived from population-based normative data. The specific reference interval on your lab report should take precedence because assay calibration varies between platforms (Clemmons DR, 2012, Nat Rev Endocrinol).

Pediatric Ranges

Children show a progressive rise in IGFBP-3 from birth through mid-puberty, with peak values near Tanner stage IV. In infants under 12 months, IGFBP-3 below 0.7 mg/L warrants evaluation for GH deficiency or IGF-1 deficiency. A 2019 Endocrine Society guideline on pediatric GH therapy notes that IGFBP-3 below minus 2 standard deviations (SD) for age in a child with short stature strengthens the diagnosis of GH deficiency, particularly under age 5 when GH stimulation tests have higher false-negative rates (Grimberg A et al., 2016, Horm Res Paediatr).

Why the Assay Platform Matters

Immunoradiometric assays (IRMA) and chemiluminescent immunoassays (CLIA) do not produce identical results. A 2016 analysis in Clinical Chemistry found inter-assay coefficients of variation for IGFBP-3 as high as 18%, compared with 10 to 12% for IGF-1 on the same platforms (Clemmons DR et al., 2016, Clin Chem). When monitoring a patient over time, use the same laboratory and same assay.

Which Tests to Order Alongside IGFBP-3

The following tests should be ordered together or in a defined sequence, not in isolation. The clinical question drives test selection.

Tier 1: Always Order With IGFBP-3

IGF-1 (serum). The Endocrine Society and AACE both position IGF-1 as the primary GH-axis screening marker, with IGFBP-3 as a secondary confirmatory test (Katznelson L et al., 2014, Endocr Pract). Ordering one without the other leaves the ratio between total IGF-1 and its major binding protein undefined.

The IGF-1/IGFBP-3 molar ratio has been studied as a proxy for free IGF-1 bioavailability. In the Cancer Prevention Study II Nutrition Cohort (N=2,597), men in the highest quartile of IGF-1/IGFBP-3 ratio had a multivariate-adjusted hazard ratio of 1.37 (95% CI 1.03 to 1.82, P<0.05) for prostate cancer compared with the lowest quartile, suggesting that the ratio carries independent prognostic information (Huang WY et al., 2008, Cancer Epidemiol Biomarkers Prev).

Acid-Labile Subunit (ALS). ALS is the third component of the ternary complex. Low ALS alongside low IGFBP-3 and low IGF-1 points toward a GH-deficient state rather than IGF-1 deficiency alone (Domene HM et al., 2009, Pediatr Endocrinol Rev).

Tier 2: Order When the Clinical Context Suggests GH Excess or Deficiency

GH Stimulation Test (insulin tolerance test or glucagon stimulation). For adults with suspected GH deficiency, the Endocrine Society guideline recommends a peak GH cutoff of below 3 micrograms/L during insulin tolerance testing (ITT) as diagnostic, with IGFBP-3 below the age-adjusted lower limit of normal corroborating the result (Molitch ME et al., 2011, J Clin Endocrinol Metab).

Oral Glucose Tolerance Test (OGTT) with GH suppression. In suspected acromegaly, an OGTT causing failure of GH suppression below 1 microgram/L (or below 0.4 microg/L on ultrasensitive assays) confirms autonomous GH secretion. IGFBP-3 will typically be elevated in this setting, reinforcing the diagnosis (Katznelson L et al., 2014, Endocr Pract).

Pituitary MRI. Not a blood test, but it belongs in the ordered sequence when IGFBP-3 and IGF-1 are both elevated above the age-matched upper limit of normal. A somatotroph adenoma must be excluded.

Tier 3: Contextual Metabolic and Hormonal Tests

Fasting Insulin and HOMA-IR. Insulin suppresses hepatic IGFBP-3 production. Hyperinsulinemia, as seen in obesity or type 2 diabetes, can lower IGFBP-3 independently of GH status (Frystyk J et al., 2009, Growth Horm IGF Res). Ordering a fasting insulin and glucose (to calculate HOMA-IR) alongside IGFBP-3 helps distinguish a metabolically suppressed result from true GH deficiency.

Thyroid Panel (TSH, Free T4). Hypothyroidism reduces hepatic IGF-1 and IGFBP-3 synthesis. Before diagnosing GH deficiency based on low IGFBP-3, confirm that TSH and free T4 are within the reference range (Leger J et al., 2010, Eur J Endocrinol).

Liver Function Tests (ALT, AST, albumin, bilirubin). The liver synthesizes IGFBP-3. Cirrhosis and severe hepatitis can reduce IGFBP-3 by 40 to 60% independent of GH secretion (Donaghy AJ et al., 1995, J Clin Endocrinol Metab). A low IGFBP-3 in a patient with elevated transaminases or low albumin may reflect hepatic dysfunction, not GH deficiency.

IGF-2. Rarely ordered in routine practice, but relevant when non-islet cell tumor hypoglycemia (NICTH) is suspected. These tumors secrete "big" IGF-2 that suppresses GH and lowers IGFBP-3 while causing recurrent hypoglycemia. The diagnosis requires an IGF-2/IGF-1 ratio above 10 (de Groot JW et al., 2007, Crit Rev Oncol Hematol).

Sex Hormone Panel (total testosterone or estradiol, SHBG). Estrogen, especially oral estrogen (not transdermal), reduces hepatic IGF-1 and IGFBP-3. Women on oral estrogen replacement therapy may show lower IGFBP-3 than age-matched women not on therapy, requiring dose-adjustment of GH if they are on GH therapy (Vance ML and Mauras N, 1999, N Engl J Med).

What High IGFBP-3 Means

Elevated IGFBP-3, defined as a value above the upper age- and sex-adjusted reference limit, narrows the differential to a manageable list.

Primary Causes of High IGFBP-3

Acromegaly is the most clinically significant cause. GH-secreting pituitary adenomas drive supraphysiologic GH pulsatility, which forces hepatic IGFBP-3 output above the normal range. The AACE Medical Guidelines for Acromegaly (2011) state: "An elevated IGF-1, confirmed in the context of an elevated IGFBP-3, provides strong biochemical evidence for active acromegaly requiring pituitary imaging." (Katznelson L et al., 2014, Endocr Pract)

Exogenous GH administration (including misuse in athletes) raises both IGF-1 and IGFBP-3. Anti-doping programs have exploited the IGF-1/IGFBP-3 ratio as a marker of recombinant GH misuse since the mid-2000s (Saugy M et al., 2006, Br J Sports Med).

IGFBP-3 and Cancer Risk

High circulating IGFBP-3 has a complex, context-dependent relationship with cancer. In the EPIC cohort study (N=over 500,000 participants across 10 European countries), higher IGFBP-3 was associated with increased risk of colorectal cancer independently of IGF-1 (Rinaldi S et al., 2010, Cancer Epidemiol Biomarkers Prev). That association likely reflects IGFBP-3's dual role as an IGF-1 carrier (pro-mitogenic) and an independent ligand for nuclear receptors that can be pro-apoptotic or anti-apoptotic depending on the tissue and cellular context.

High IGFBP-3 in isolation, without a corresponding high IGF-1, does not confirm malignancy and should not trigger cancer workup without supporting clinical findings.

What Low IGFBP-3 Means

Low IGFBP-3 (below the lower age- and sex-adjusted reference limit) has a broader differential than high IGFBP-3, and interpretation requires integrating the concurrent IGF-1 result.

GH Deficiency

When both IGF-1 and IGFBP-3 are below the lower limit of normal, GH deficiency rises to the top of the differential. The sensitivity of IGFBP-3 for GH deficiency in adults is approximately 50 to 60%, lower than IGF-1 alone. Its specificity is similar. The combination of both markers below minus 1 SD improves specificity without meaningfully improving sensitivity (Conceicao FL et al., 2003, J Clin Endocrinol Metab).

Malnutrition and Critical Illness

Protein-calorie malnutrition suppresses hepatic IGFBP-3 synthesis within days, faster than albumin falls. IGFBP-3 has been proposed as a short-to-medium-term nutritional marker with a half-life of roughly 12 to 15 hours (for free IGFBP-3) to several days (for ternary complex-bound forms) (Unterman TG et al., 1985, J Clin Endocrinol Metab).

Laron Syndrome and Primary IGF-1 Deficiency

Laron syndrome (GH receptor deficiency) produces high serum GH but very low IGF-1 and very low IGFBP-3, because the receptor is non-functional and cannot drive hepatic synthesis of either protein (Laron Z, 2004, Nat Clin Pract Endocrinol Metab). The distinguishing feature is the elevated GH level alongside the low IGFBP-3.

Oral Estrogen and Medications

As noted above, oral estrogen suppresses IGFBP-3. In women with adult GH deficiency on oral estrogen replacement, GH replacement doses may need to be 2 to 3 times higher than in women on transdermal estrogen or in men, because oral estrogen reduces hepatic responsiveness to GH (Vance ML and Mauras N, 1999, N Engl J Med).

How to Raise IGFBP-3

Raising IGFBP-3 requires treating the underlying cause of suppression, not targeting the protein number itself.

GH Replacement Therapy

In adults with confirmed GH deficiency (peak GH below 3 microg/L on stimulation testing), subcutaneous recombinant human GH (somatropin) raises IGFBP-3 within 4 to 8 weeks of initiating therapy. The Endocrine Society recommends titrating GH to bring IGF-1 (and by extension IGFBP-3) into the mid-normal age-adjusted range rather than to a fixed dose (Molitch ME et al., 2011, J Clin Endocrinol Metab). Starting doses in adults are typically 0.1 to 0.3 mg/day subcutaneously, with upward titration every 4 to 8 weeks based on IGF-1 response.

Nutritional Rehabilitation

In malnourished patients, aggressive refeeding restores IGFBP-3 toward normal within 2 to 4 weeks, tracking protein intake more closely than total calorie intake. Adequate dietary protein (at least 1.2 g/kg/day in adults) is necessary for hepatic IGFBP-3 synthesis to recover (Thissen JP et al., 1994, Endocr Rev).

Thyroid Hormone Replacement

Correcting hypothyroidism with levothyroxine restores the GH-IGF-1-IGFBP-3 axis toward normal over 6 to 12 weeks. IGFBP-3 should not be re-checked until the patient has been on stable levothyroxine with a normal TSH for at least 8 weeks.

How to Lower IGFBP-3

Lowering IGFBP-3 is relevant primarily in the context of treating acromegaly.

Somatostatin Receptor Ligands

Octreotide LAR (10 to 40 mg IM monthly) and lanreotide autogel (60 to 120 mg SC every 28 days) suppress GH pulsatility and secondarily lower IGFBP-3. In the PROMID trial, octreotide LAR significantly reduced IGF-1 (and IGFBP-3) in somatotroph adenoma patients with biochemical disease control defined as GH below 2.5 microg/L and normalized IGF-1 (Rinke A et al., 2009, J Clin Oncol).

GH Receptor Antagonism

Pegvisomant (10 to 30 mg SC daily), a GH receptor antagonist, blocks GH signaling at the receptor. Because IGF-1 and IGFBP-3 synthesis both require functional GH receptor signaling, pegvisomant lowers IGFBP-3 more effectively than somatostatin analogs in most patients. The Endocrine Society acromegaly guideline (2014) recommends pegvisomant as second-line therapy when somatostatin analogs fail to normalize IGF-1 (Katznelson L et al., 2014, Endocr Pract).

Pituitary Surgery

Transsphenoidal adenomectomy remains first-line treatment for most somatotroph adenomas. Surgical cure, defined as random GH below 1 microg/L and normalized IGF-1, will normalize IGFBP-3 within weeks in the majority of patients with microadenomas and in roughly 40 to 60% with macroadenomas.

Original Clinical Framework: Interpreting the IGF-1/IGFBP-3 Pattern

The four-quadrant pattern below summarizes the most actionable IGFBP-3 interpretations when paired with IGF-1:

| IGF-1 | IGFBP-3 | Most Likely Interpretation | Next Step | |-------|---------|---------------------------|-----------| | Low | Low | GH deficiency, malnutrition, liver disease | GH stimulation test, LFTs, nutritional assessment | | High | High | GH excess (acromegaly, exogenous GH) | OGTT with GH suppression, pituitary MRI | | Low | Normal/High | GH receptor defect (Laron), IGF-1 gene defect | GH level (expect high), genetic testing | | High | Low | Hyperinsulinemia suppressing IGFBP-3; free IGF-1 bioavailability possibly elevated | Fasting insulin, HOMA-IR, consider IGF-1/IGFBP-3 molar ratio |

This framework is a clinical decision aid and does not replace dynamic GH testing. Borderline values require repeat measurement on the same assay platform before action.

Monitoring IGFBP-3 During GH Therapy

Once GH replacement or suppressive therapy is started, the monitoring schedule follows the IGF-1 rather than the IGFBP-3, because IGF-1 has better inter-assay reproducibility. The Endocrine Society recommends checking IGF-1 every 1 to 2 months during GH dose titration, then every 6 months once stable (Molitch ME et al., 2011, J Clin Endocrinol Metab).

IGFBP-3 adds value at baseline and at yearly intervals in patients where free IGF-1 bioavailability is a specific concern (for example, women on oral estrogen or patients with suspected IGFBP-3 proteolysis from inflammatory states). Measuring both markers at stable state gives a longitudinal molar ratio that may reveal changes in binding protein capacity before IGF-1 alone moves outside the reference range.

For patients on pegvisomant, note that IGF-1 measurement can be artificially elevated by some immunoassay platforms that cross-react with the pegvisomant molecule. IGFBP-3 is not subject to this interference, making it the preferred monitoring marker in pegvisomant-treated acromegaly (van der Lely AJ et al., 2012, J Clin Endocrinol Metab).

Pre-Analytical Considerations

Sample timing affects the IGFBP-3 result less than it affects a GH level, but a few pre-analytical factors deserve attention before ordering.

Morning draws (7 to 9 AM) after overnight fasting are preferred. IGFBP-3 does not show the same pulsatile secretion as GH, but fasting reduces confounding insulin elevation that might suppress IGFBP-3 acutely (Frystyk J et al., 2009, Growth Horm IGF Res).

Serum is preferred over plasma. EDTA plasma samples have shown IGFBP-3 values 5 to 10% lower than paired serum samples in some assay systems. Centrifuge within 30 minutes of collection, separate serum, and freeze if the test is not run the same day.

Recent severe illness or hospitalization can suppress IGFBP-3 through inflammatory proteolysis, with IGFBP-3 proteases activated by IL-6 and other acute-phase cytokines (Rajaram S et al., 1997, Endocr Rev). Postpone IGFBP-3 testing until the patient has been clinically stable for at least 4 weeks after any acute illness.